This is the authors' abstract. We don't add key points for this paper.
Abnormal activation of SETBP1 due to overexpression or missense mutations occurs frequently in various myeloid neoplasms and associates with poor prognosis. Direct activation of Hoxa9/Hoxa10/Myb transcription by SETBP1 and its missense mutants is essential for their transforming capability; however, the underlying epigenetic mechanisms remain elusive. We found that both SETBP1 and its missense mutant SETBP1(D/N) directly interact with histone methyltransferase MLL1. Using a combination of ChIP-seq and RNA-seq analysis in primary hematopoietic stem and progenitor cells, we uncovered extensive overlap in their genomic occupancy and their cooperation in activating many oncogenic transcription factor genes including Hoxa9/Hoxa10/Myb and a large group of ribosomal protein genes. Genetic ablation of Mll 1 as well as treatment with an inhibitor of the MLL1 complex OICR-9429 abrogated Setbp1/Setbp1(D/N) -induced transcriptional activation and transformation. Thus, the MLL1 complex plays a critical role in Setbp1 -induced transcriptional activation and transformation and represents a promising target for treating myeloid neoplasms with SETBP1 activation.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: